Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Apoptosis
New research on apoptosis from P. Revill and co-authors summarized
July 29th, 2008
"Elesclomol (STA-4783) is a small molecule that induces apoptosis via the mitochondrial apoptotic pathway in cancer cells by increasing oxidative stress, while having little or no effect on normal cells. The agent acts synergistically with established chemotherapeutic agents, including paclitaxel, to eradicate tumors in a range of human tumor xenograft models," scientists writing in the journal Drugs of the Future report. "Combination of elesclomol and paclitaxel was associated with little toxicity above that seen with paclitaxel alone in preclinical models and in a phase I trial. In a phase II trial in patients with metastatic melanoma, treatment with elesclomol...
Source: Cancer Weekly (2008-07-29)
|
